Amicus Therapeutics, INC Form 4 insider transactions

Amicus Therapeutics' CEO, Bradley Campbell, exercised stock options and sold shares on August 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Amicus Therapeutics' CEO, Bradley Campbell, exercised stock options and sold shares on July 5, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Amicus Therapeutics' CEO, Bradley Campbell, exercised stock options and sold a portion of the acquired shares on July 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Burke Whitman reported the acquisition of restricted stock units and stock options in Amicus Therapeutics on June 6, 2024.

Director Craig A. Wheeler reports acquisition of restricted stock units and stock options in Amicus Therapeutics.

Director Eiry Roberts acquired shares and stock options in Amicus Therapeutics, according to a recent SEC Form 4 filing.

Director Lynn Dorsey Bleil reports acquiring 11,847 restricted stock units and 42,467 stock options in Amicus Therapeutics.

Director Michael Kelly reported the acquisition of restricted stock units and stock options, as well as the disposal of common stock.

Director Glenn Sblendorio reports acquisition of Amicus Therapeutics shares and stock options in a recent SEC filing.

Director Michael Raab reports acquisition of stock options and restricted stock units in Amicus Therapeutics.

Director Margaret McGlynn reports acquisition of restricted stock units and stock options in Amicus Therapeutics.

Amicus Therapeutics' CEO, Bradley Campbell, exercised stock options and sold shares on June 3, 2024, according to a recent SEC Form 4 filing.

Amicus Therapeutics' CEO, Bradley Campbell, exercised stock options and sold shares on May 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Samantha Prout, Chief Accounting Officer of Amicus Therapeutics, disposed of 7,027 shares of common stock on April 15, 2024.

Amicus Therapeutics' CEO, Bradley Campbell, exercised stock options and sold shares on April 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Bradley Campbell, President and CEO of Amicus Therapeutics, disposed of 13,375 shares of common stock on March 15, 2024, to cover tax obligations.

Amicus Therapeutics CEO Bradley Campbell amended a previous Form 4 filing to accurately reflect stock acquisitions related to a performance-based restricted stock unit (PRSU) award and to correct holdings after tax withholdings.

John Crowley, Executive Chairman of Amicus Therapeutics, files an amended SEC Form 4 to correct previously reported transactions involving common stock, including acquisitions and disposals.

David Michael Clark, Chief People Officer at Amicus Therapeutics, amends a previous SEC Form 4 filing to accurately reflect stock acquisitions from a performance-based restricted stock unit (PRSU) award and correct holdings after tax withholdings.

Jeff Castelli, Chief Development Officer at Amicus Therapeutics, amends a previous SEC filing to accurately reflect stock acquisitions and holdings following the vesting of performance-based restricted stock units (PRSUs) and subsequent tax withholdings.

Ellen Rosenberg, Chief Legal Officer of Amicus Therapeutics, files an amendment to a previous SEC Form 4 to accurately reflect stock acquisitions and holdings following a performance-based restricted stock unit (PRSU) award and tax withholdings.

Director Glenn Sblendorio exercised stock options to acquire 15,000 shares of Amicus Therapeutics common stock at $2.8 per share on March 7, 2024.

Director Michael Raab exercised stock options to acquire 15,000 shares of Amicus Therapeutics common stock at $2.80 per share on March 5, 2024.

Director Margaret McGlynn exercised stock options and sold shares of Amicus Therapeutics, Inc. under a pre-arranged Rule 10b5-1 trading plan.

Amicus Therapeutics' CEO, Bradley Campbell, reports exercising stock options and selling shares under a pre-arranged Rule 10b5-1 trading plan.

John F. Crowley, Executive Chairman of Amicus Therapeutics, sold 29,181 shares of common stock at an average price of $13.3492 on March 1, 2024, according to a Form 4 filing with the SEC.